An observational study in Respiratory Tract Infections and Respiratory Syncytial Virus Infections, sponsored by Uppsala University. Completed at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2022-05-31.
Sponsored by Uppsala University · Observational
Infection with human respiratory syncytial (RS) virus is the most common cause of hospital stay due to pediatric lower respiratory tract infection. An exaggerated immune response contributes to the pathogenesis and small children may have over reactive airways for a long time after an infection.
New research has shown that polymorphonuclear leukocytes (PMNs) are stimulated by the virus. Besides fighting the infection they also cause collateral damage to the host. Among other mechanisms PMNs stimulates mucus formation that affects breathing. They also secrete enzymes, toxic proteins and free radicals that may cause harm to lung tissue and airways.
The current project strives towards identifying and quantifying inflammatory mediators in sputum, urine and blood of children with severe RS-virus infection. The ultimate aim of the project is to, in detail, describe proteins contributing to the pathogenesis of the disease.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 31 is below the median of 240 across 2,136 observational studies indexed under Infections.
Browse Infections studies →Uppsala University is the lead sponsor of 381 studies on the registry; 84 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Children admitted to pediatric ICU
Exclusion Criteria:
Patients admitted to the pediatric ICU with verified or suspected RS-virus infection that are mechanically ventilated.
Other: RS-virus infection
Patients admitted to the pediatric ICU due to a cause other than a verified or suspected respiratory tract infection.
Other: RS-virus infection
The intervention consists of lower respiratory tract infection due to RS-virus
Levels of inflammatory mediators in sputum
Simultaneous detection and quantification of hundreds of potential mediators using mass-spectrometry
Time frame: Up to three weeks
Levels of inflammatory mediators in blood
Simultaneous detection and quantification of hundreds of potential mediators using mass-spectrometry
Time frame: Up to three weeks
Levels of inflammatory mediators in urine
Simultaneous detection and quantification of hundreds of potential mediators using mass-spectrometry
Time frame: Up to three weeks
Disease severity as measured by sequential organ failure assessment score (SOFA-score)
Time frame: Up to 30-days
Lung function as measured in respirator
Time frame: Up to 30-days
Lung function as measured by spirometry
Time frame: Within 1 year
Lung function as measured by spirometry
Time frame: Within 10 years
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Uppsala University